Hackettstown-based Genomic Prediction and Livingston-based Cooper Genomics face federal class action lawsuits alleging false advertising of PGT-A embryo testing.
Allison Freeman, an attorney representing the plaintiffs, said patients purchase the testing because it’s sold as having “high percentages of accuracy.”
The testing, which is rarely covered by insurance, is offered as an optional add-on during the IVF process. Although it’s marketed as increasing pregnancy and live birth rates, major medical organizations have stated that further research is necessary to establish its value.
The American Society for Reproductive Medicine published a practice guideline in 2018 concluding “there is insufficient evidence to recommend the routine use of preimplantation genetic testing-aneuploidy in all infertile women.”
Despite this, the proportion of IVF cycles using PGT-A increased from 14% in 2014 to 44% in 2019, according to national data from the Society for Assisted Reproductive Technology.